Spatial dynamics of TRAIL death receptors in cancer cells

Drug Resistance Updates

Volumn 19, Issue , 2015, Pages 13-21

  Twomey, Julianne D ^a   Kim, Su Ryun ^a   Zhao, Liqun ^a   Bozza, William P ^a   Zhang, Baolin ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Death receptors; Drug resistance; Surface expression; Targeted cancer therapy; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84937759446     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2015.02.001     Document Type: Review

References (130)

1. J. Abdulghani, J.E. Allen, D.T. Dicker, Y.Y. Liu, D. Goldenberg, C.D. Smith, R. Humphreys, and W.S. El-Deiry Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis PLOS ONE 8 2013 e75414
2. Y. Adar, M. Stark, E.E. Bram, P. Nowak-Sliwinska, H. van den Bergh, G. Szewczyk, T. Sarna, A. Skladanowski, A.W. Griffioen, and Y.G. Assaraf Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers Cell Death Dis. 3 2012 e293
3. N. Ahmad, H.J. Gabius, S. Andre, H. Kaltner, S. Sabesan, R. Roy, B. Liu, F. Macaluso, and C.F. Brewer Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes J. Biol. Chem. 279 2004 10841 10847
4. Y. Akazawa, J.L. Mott, S.F. Bronk, N.W. Werneburg, A. Kahraman, M.E. Guicciardi, X.W. Meng, S. Kohno, V.H. Shah, S.H. Kaufmann, M.A. McNiven, and G.J. Gores Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines Gastroenterology 136 2009 2365 2376
5. C.D. Austin, D.A. Lawrence, A.A. Peden, E.E. Varfolomeev, K. Totpal, A.M. De Maziere, J. Klumperman, D. Arnott, V. Pham, R.H. Scheller, and A. Ashkenazi Death-receptor activation halts clathrin-dependent endocytosis Proc. Natl. Acad. Sci. U.S.A. 103 2006 10283 10288
6. P. Aza-Blanc, C.L. Cooper, K. Wagner, S. Batalov, Q.L. Deveraux, and M.P. Cooke Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening Mol. Cell 12 2003 627 637
7. S. Baritaki, S. Huerta-Yepez, T. Sakai, D.A. Spandidos, and B. Bonavida Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1 Mol. Cancer Ther. 6 2007 1387 1399
8. S. Baritaki, A. Katsman, D. Chatterjee, K.C. Yeung, D.A. Spandidos, and B. Bonavida Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation J. Immunol. 179 2007 5441 5453
9. S. Baritaki, E. Suzuki, K. Umezawa, D.A. Spandidos, J. Berenson, T.R. Daniels, M.L. Penichet, A.R. Jazirehi, M. Palladino, and B. Bonavida Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells J. Immunol. 180 2008 6199 6210
10. A.C. Castro, N. Terziyska, M. Grunert, S. Gundisch, U. Graubner, L. Quintanilla-Martinez, and I. Jeremias Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL Blood 119 2012 4224 4227
11. J.J. Chen, W.P. Bozza, X. Di, Y. Zhang, W. Hallett, and B. Zhang H-Ras regulation of TRAIL death receptor mediated apoptosis Oncotarget 5 2014 5125 5137
12. J.J. Chen, H.C. Shen, L.A. Rivera Rosado, Y. Zhang, X. Di, and B. Zhang Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells Oncotarget 3 2012 833 842
13. Q. Chen, S. Ganapathy, K.P. Singh, S. Shankar, and R.K. Srivastava Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells PLoS ONE 5 2010 e15288
14. X. Chen, K. Kandasamy, and R.K. Srivastava Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling Cancer Res. 63 2003 1059 1066
15. M. Chiariello, J.P. Vaque, P. Crespo, and J.S. Gutkind Activation of Ras and Rho GTPases and MAP Kinases by G-protein-coupled receptors Methods Mol. Biol. 661 2010 137 150
16. Y.H. Choi, and A.M. Yu ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development Curr. Pharm. Des. 20 2014 793 807
17. R.N. Crowder, and W.S. El-Deiry Caspase-8 regulation of TRAIL-mediated cell death Exp. Oncol. 34 2012 160 164
18. D. Daniel, and N.S. Wilson Tumor necrosis factor: renaissance as a cancer therapeutic? Curr. Cancer Drug Targets 8 2008 124 131
19. L.H. de Wilt, G. Jansen, Y.G. Assaraf, M.J. van, J. Cloos, A.D. Schimmer, E.T. Chan, C.J. Kirk, G.J. Peters, and F.A. Kruyt Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer Biochem. Pharmacol. 83 2012 207 217
20. X. Di, G. Zhang, Y. Zhang, K. Takeda, L.A. Rivera Rosado, and B. Zhang Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5 Oncotarget 4 2013 1349 1364
21. L.Y. Dimberg, C.K. Anderson, R. Camidge, K. Behbakht, A. Thorburn, and H.L. Ford On the TRAIL to successful cancer therapy?. Predicting and counteracting resistance against TRAIL-based therapeutics Oncogene 32 2013 1341 1350
22. J. Downward Targeting RAS signalling pathways in cancer therapy Nat. Rev. Cancer 3 2003 11 22
23. K.G. Drosopoulos, M.L. Roberts, L. Cermak, T. Sasazuki, S. Shirasawa, L. Andera, and A. Pintzas Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway J. Biol. Chem. 280 2005 22856 22867
24. A. Eggert, M.A. Grotzer, T.J. Zuzak, B.R. Wiewrodt, R. Ho, N. Ikegaki, and G.M. Brodeur Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression Cancer Res. 61 2001 1314 1319
25. D.J. Fall, H. Stessman, S.S. Patel, Z. Sachs, B.G. Van Ness, L.B. Baughn, and M.A. Linden Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma J. Cancer 5 2014 720 727
26. S. Fulda Targeting extrinsic apoptosis in cancer: challenges and opportunities Semin. Cell Dev. Biol. 2015 10.1016/j.semcdb.2015.01.006
27. S. Fulda, M.U. Kufer, E. Meyer, V.F. van, B. Dockhorn-Dworniczak, and K.M. Debatin Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer Oncogene 20 2001 5865 5877
28. S. Ganapathy, Q. Chen, K.P. Singh, S. Shankar, and R.K. Srivastava Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor PLoS ONE 5 2010 e15627
29. V. Goler-Baron, and Y.G. Assaraf Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics PLoS ONE 7 2012 e35487
30. B. Guan, P. Yue, G.L. Clayman, and S.Y. Sun Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene J. Cell Physiol. 188 2001 98 105
31. B. Guan, P. Yue, R. Lotan, and S.Y. Sun Evidence that the human death receptor 4 is regulated by activator protein 1 Oncogene 21 2002 3121 3129
32. J.Y. Guo, H.Y. Chen, R. Mathew, J. Fan, A.M. Strohecker, G. Karsli-Uzunbas, J.J. Kamphorst, G. Chen, J.M. Lemons, V. Karantza, H.A. Coller, R.S. Dipaola, C. Gelinas, J.D. Rabinowitz, and E. White Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis Genes Dev. 25 2011 460 470
33. J. Han, W. Hou, L.A. Goldstein, C. Lu, D.B. Stolz, X.M. Yin, and H. Rabinowich Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells J. Biol. Chem. 283 2008 19665 19677
34. V. Haselmann, A. Kurz, U. Bertsch, S. Hubner, M. Olempska-Muller, J. Fritsch, R. Hasler, A. Pickl, H. Fritsche, F. Annewanter, C. Engler, B. Fleig, A. Bernt, C. Roder, H. Schmidt, C. Gelhaus, C. Hauser, J.H. Egberts, C. Heneweer, A.M. Rohde, C. Boger, U. Knippschild, C. Rocken, D. Adam, H. Walczak, S. Schutze, O. Janssen, F.G. Wulczyn, H. Wajant, H. Kalthoff, and A. Trauzold Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells Gastroenterology 146 2014 278 290
35. W. He, Q. Wang, J. Xu, X. Xu, M.T. Padilla, G. Ren, X. Gou, and Y. Lin Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving T Autophagy 8 2012 1811 1821
36. J. Held, and K. Schulze-Osthoff Potential and caveats of TRAIL in cancer therapy Drug Resist. Update 4 2001 243 252
37. R.S. Herbst, S.G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P.J. O'Dwyer, M.S. Gordon, W. Novotny, M.A. Goldwasser, T.M. Tohnya, B.L. Lum, A. Ashkenazi, A.M. Jubb, and D.S. Mendelson Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J. Clin. Oncol. 28 2010 2839 2846
38. G. Herrero-Martin, M. Hoyer-Hansen, C. Garcia-Garcia, C. Fumarola, T. Farkas, A. Lopez-Rivas, and M. Jaattela TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells EMBO J. 28 2009 677 685
39. S. Hinz, A. Trauzold, L. Boenicke, C. Sandberg, S. Beckmann, E. Bayer, H. Walczak, H. Kalthoff, and H. Ungefroren Bcl-XL protects pancreatic adenocarcinoma cells against Oncogene 19 2000 5477 5486
40. M. Holderfield, T.E. Nagel, and D.D. Stuart Mechanism and consequences of RAF kinase activation by small-molecule inhibitors Br. J. Cancer 111 2014 640 645
41. W. Hou, J. Han, C. Lu, L.A. Goldstein, and H. Rabinowich Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis Autophagy 6 2010 891 900
42. H.O. Jin, Y.H. Lee, J.A. Park, J.H. Kim, S.E. Hong, H.A. Kim, E.K. Kim, W.C. Noh, B.H. Kim, S.K. Ye, Y.H. Chang, S.I. Hong, Y.J. Hong, I.C. Park, and J.K. Lee Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition Biochem. Biophys. Res. Commun. 444 2014 502 508
43. Z. Jin, E.R. McDonald III, D.T. Dicker, and W.S. El-Deiry Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis J. Biol. Chem. 279 2004 35829 35839
44. H. Kanzaki, A. Ohtaki, F.K. Merchant, M.I. Greene, and R. Murali Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells Exp. Mol. Pathol. 94 2013 372 379
45. M.M. Keane, S.A. Ettenberg, M.M. Nau, E.K. Russell, and S. Lipkowitz Chemotherapy augments TRAIL-induced apoptosis in breast cell lines Cancer Res. 59 1999 734 741
46. S.Y. Kim, J.H. Kim, and J.J. Song c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5 Cancer Gene Ther. 20 2013 82 87
47. F.C. Kischkel, D.A. Lawrence, A. Chuntharapai, P. Schow, K.J. Kim, and A. Ashkenazi Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5 Immunity 12 2000 611 620
48. F.C. Kischkel, D.A. Lawrence, A. Tinel, H. LeBlanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Arnott, and A. Ashkenazi Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 J. Biol. Chem. 276 2001 46639 46646
49. T. Knight, and J.A. Irving Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting Front. Oncol. 4 2014 160
50. S.L. Kohlhaas, A. Craxton, X.M. Sun, M.J. Pinkoski, and G.M. Cohen Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis J. Biol. Chem. 282 2007 12831 12841
51. Y. Kojima, M. Nakayama, T. Nishina, H. Nakano, M. Koyanagi, K. Takeda, K. Okumura, and H. Yagita Importin beta1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells J. Biol. Chem. 286 2011 43383 43393
52. S. Kurita, J.L. Mott, L.L. Almada, S.F. Bronk, N.W. Werneburg, S.Y. Sun, L.R. Roberts, M.E. Fernandez-Zapico, and G.J. Gores GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis Oncogene 29 2010 4848 4858
53. D. Lawrence, Z. Shahrokh, S. Marsters, K. Achilles, D. Shih, B. Mounho, K. Hillan, K. Totpal, L. Deforge, P. Schow, J. Hooley, S. Sherwood, R. Pai, S. Leung, L. Khan, B. Gliniak, J. Bussiere, C.A. Smith, S.S. Strom, S. Kelley, J.A. Fox, D. Thomas, and A. Ashkenazi Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions Nat. Med. 7 2001 383 385
54. K. Leithner, E. Stacher, R. Wurm, F. Ploner, F. Quehenberger, C. Wohlkoenig, Z. Balint, J. Polachova, A. Olschewski, H. Samonigg, H.H. Popper, and H. Olschewski Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy Lung Cancer 65 2009 98 104
55. S. Leong, R.B. Cohen, D.L. Gustafson, C.J. Langer, D.R. Camidge, K. Padavic, L. Gore, M. Smith, L.Q. Chow, M.M. von, C. O'Bryant, S. Hariharan, S. Diab, N.L. Fox, R. Miceli, and S.G. Eckhardt Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study J. Clin. Oncol. 27 2009 4413 4421
56. G.C. Liu, J. Zhang, S.G. Liu, R. Gao, Z.F. Long, K. Tao, and Y.F. Ma Detachment of esophageal carcinoma cells from extracellular matrix causes relocalization of death receptor 5 and apoptosis World J. Gastroenterol. 15 2009 836 844
57. D. Mahalingam, A. Mita, K. Sankhala, R. Swords, K. Kelly, F. Giles, and M.M. Mita Targeting sarcomas: novel biological agents and future perspectives Curr. Drug Targets 10 2009 937 949
58. N. Mazurek, J.C. Byrd, Y. Sun, M. Hafley, K. Ramirez, J. Burks, and R.S. Bresalier Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells Cell Death Differ. 19 2012 523 533
59. G. Mellier, and S. Pervaiz The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS) Free Radic. Res. 46 2012 996 1003
60. F.J. Mendoza, G. Ishdorj, X. Hu, and S.B. Gibson Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment Apoptosis 13 2008 756 770
61. K.R. Mills, M. Reginato, J. Debnath, B. Queenan, and J.S. Brugge Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro Proc. Natl. Acad. Sci. U.S.A. 101 2004 3438 3443
62. D.O. Moon, C.H. Kang, S.H. Kang, Y.H. Choi, J.W. Hyun, W.Y. Chang, H.K. Kang, Y.S. Koh, Y.H. Maeng, Y.R. Kim, and G.Y. Kim Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx Toxicol. Appl. Pharmacol. 259 2012 87 95
63. N. Naslavsky, R. Weigert, and J.G. Donaldson Characterization of a nonclathrin endocytic pathway: membrane cargo and lipid requirements Mol. Biol. Cell 15 2004 3542 3552
64. A. Nesterov, M. Nikrad, T. Johnson, and A.S. Kraft Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis Cancer Res. 64 2004 3922 3927
65. D. Niewerth, G. Jansen, L.F. Riethoff, M.J. van, A.J. Kale, B.S. Moore, Y.G. Assaraf, J.L. Anderl, S. Zweegman, G.J. Kaspers, and J. Cloos Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib) Mol. Pharmacol. 86 2014 12 19
66. D. Niewerth, G.J. Kaspers, Y.G. Assaraf, M.J. van, C.J. Kirk, J. Anderl, J.L. Blank, P.M. van de Ven, S. Zweegman, G. Jansen, and J. Cloos Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines J. Hematol. Oncol. 7 2014 7
67. D. Niewerth, M.J. van, G. Jansen, Y.G. Assaraf, T.C. Hendrickx, C.J. Kirk, J.L. Anderl, S. Zweegman, G.J. Kaspers, and J. Cloos Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924 Biochem. Pharmacol. 89 2014 43 51
68. T.K. Niu, Y. Cheng, X. Ren, and J.M. Yang Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis FEBS Lett. 584 2010 3519 3524
69. M. O'Hayre, M.S. Degese, and J.S. Gutkind Novel insights into G protein and G protein-coupled receptor signaling in cancer Curr. Opin. Cell Biol. 27 2014 126 135
70. Y.T. Oh, X. Liu, P. Yue, S. Kang, J. Chen, J. Taunton, F.R. Khuri, and S.Y. Sun ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1 J. Biol. Chem. 285 2010 41310 41319
71. Y.T. Oh, P. Yue, W. Zhou, J.M. Balko, E.P. Black, T.K. Owonikoko, F.R. Khuri, and S.Y. Sun Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling J. Biol. Chem. 287 2012 257 267
72. E. Oikonomou, K. Kothonidis, E. Taoufik, E. Probert, G. Zografos, G. Nasioulas, L. Andera, and A. Pintzas Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo Br. J. Cancer 97 2007 73 84
73. Y. Okada, H. Miyamoto, T. Goji, and T. Takayama Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer Digestion 89 2014 18 23
74. R.Z. Orlowski Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Semin. Oncol. 40 2013 634 651
75. W. Ouyang, C. Yang, Y. Liu, J. Xiong, J. Zhang, Y. Zhong, G. Zhang, F. Zhou, Y. Zhou, and C. Xie Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells Int. J. Oncol. 39 2011 1577 1586
76. N. Ozoren, and W.S. El-Deiry Cell surface death receptor signaling in normal and cancer cells Semin. Cancer Biol. 13 2003 135 147
77. E.A. Partridge, R.C. Le, G.M. Di Guglielmo, J. Pawling, P. Cheung, M. Granovsky, I.R. Nabi, J.L. Wrana, and J.W. Dennis Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis Science 306 2004 120 124
78. J. Peli, M. Schroter, C. Rudaz, M. Hahne, C. Meyer, E. Reichmann, and J. Tschopp Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas EMBO J. 18 1999 1824 1831
79. N. Porat-Shliom, Y. Kloog, and J.G. Donaldson A unique platform for H-Ras signaling involving clathrin-independent endocytosis Mol. Biol. Cell 19 2008 765 775
80. I.A. Prior, A. Harding, J. Yan, J. Sluimer, R.G. Parton, and J.F. Hancock GTP-dependent segregation of H-ras from lipid rafts is required for biological activity Nat. Cell Biol. 3 2001 368 375
81. F.H. Psahoulia, K.G. Drosopoulos, L. Doubravska, L. Andera, and A. Pintzas Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts Mol. Cancer Ther. 6 2007 2591 2599
82. Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi RAS oncogenes: weaving a tumorigenic web Nat. Rev. Cancer 11 2011 761 774
83. R. Ravi, G.C. Bedi, L.W. Engstrom, Q. Zeng, B. Mookerjee, C. Gelinas, E.J. Fuchs, and A. Bedi Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB Nat. Cell Biol. 3 2001 409 416
84. M.D. Resh Palmitoylation of ligands, receptors, and intracellular signaling molecules Sci. STKE 2006 2006 re14
85. C.W. Reuter, M.A. Morgan, and L. Bergmann Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96 2000 1655 1669
86. N.J. Roberts, S. Zhou, L.A. Diaz Jr.; and M. Holdhoff Systemic use of tumor necrosis factor alpha as an anticancer agent Oncotarget 2 2011 739 751
87. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
88. R.P. Sahu, S. Batra, P.K. Kandala, T.L. Brown, and S.K. Srivastava The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines Cancer Chemother. Pharmacol. 67 2011 481 487
89. E. Schmukler, Y. Kloog, and R. Pinkas-Kramarski Ras and autophagy in cancer development and therapy Oncotarget 5 2014 577 586
90. S. Shankar, and R.K. Srivastava Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications Drug Resist. Update 7 2004 139 156
91. A. Shapira, Y.D. Livney, H.J. Broxterman, and Y.G. Assaraf Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance Drug Resist. Update 14 2011 150 163
92. M.S. Sheikh, T.F. Burns, Y. Huang, G.S. Wu, S. Amundson, K.S. Brooks, A.J. Fornace Jr.; and W.S. El-Deiry p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha Cancer Res. 58 1998 1593 1598
93. S. Shetty, J.B. Gladden, E.S. Henson, X. Hu, J. Villanueva, N. Haney, and S.B. Gibson Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines Apoptosis 7 2002 413 420
94. S. Shetty, B.A. Graham, J.G. Brown, X. Hu, N. Vegh-Yarema, G. Harding, J.T. Paul, and S.B. Gibson Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1 Mol. Cell Biol. 25 2005 5404 5416
95. M. Shoeb, K.V. Ramana, and S.K. Srivastava Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors Free Radic. Biol. Med. 63 2013 280 290
96. M.D. Siegelin Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis Expert Opin. Ther. Targets 16 2012 801 817
97. S. Simova, M. Klima, L. Cermak, V. Sourkova, and L. Andera Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane Apoptosis 13 2008 423 436
98. T.R. Singh, S. Shankar, X. Chen, M. Asim, and R.K. Srivastava Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo Cancer Res. 63 2003 5390 5400
99. T.R. Singh, S. Shankar, and R.K. Srivastava HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma Oncogene 24 2005 4609 4623
100. A.L. Snow, M. Vaysberg, S.M. Krams, and O.M. Martinez EBV B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis Am. J. Transpl. 6 2006 976 985
101. J.H. Song, M.C. Tse, A. Bellail, S. Phuphanich, F. Khuri, N.M. Kneteman, and C. Hao Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells Cancer Res. 67 2007 6946 6955
102. J.J. Song, M.J. Szczepanski, S.Y. Kim, J.H. Kim, J.Y. An, Y.T. Kwon, M.A. Alcala Jr.; D.L. Bartlett, and Y.J. Lee c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance Cell. Signal. 22 2010 553 563
103. J.C. Soria, Z. Mark, P. Zatloukal, B. Szima, I. Albert, E. Juhasz, J.L. Pujol, J. Kozielski, N. Baker, D. Smethurst, Y.J. Hei, A. Ashkenazi, H. Stern, L. Amler, Y. Pan, and F. Blackhall Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer J. Clin. Oncol. 29 2011 4442 4451
104. J.H. Stegehuis, L.H. de Wilt, E.G. de Vries, H.J. Groen, J.S. de, and F.A. Kruyt TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives Drug Resist. Update 13 2010 2 15
105. K. Suda, K. Tomizawa, and T. Mitsudomi Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation Cancer Metastasis Rev. 29 2010 49 60
106. R. Takimoto, and W.S. El-Deiry Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site Oncogene 19 2000 1735 1743
107. A. Thorburn, K. Behbakht, and H. Ford TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them Drug Resist. Update 11 2008 17 24
108. T. Troiani, S. Zappavigna, E. Martinelli, S.R. Addeo, P. Stiuso, F. Ciardiello, and M. Caraglia Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance Expert Opin. Biol. Ther. 13 2013 241 255
109. C.M. van Geelen, E.G. de Vries, and J.S. de Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Drug Resist. Update 7 2004 345 358
110. I.A. van Roosmalen, W.J. Quax, and F.A. Kruyt Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function? Biochem. Pharmacol. 91 2014 447 456
111. J.P. Vaque, R.T. Dorsam, X. Feng, R. Iglesias-Bartolome, D.J. Forsthoefel, Q. Chen, A. Debant, M.A. Seeger, B.R. Ksander, H. Teramoto, and J.S. Gutkind A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors Mol. Cell 49 2013 94 108
112. K.W. Wagner, E.A. Punnoose, T. Januario, D.A. Lawrence, R.M. Pitti, K. Lancaster, D. Lee, G.M. von, S.F. Yee, K. Totpal, L. Huw, V. Katta, G. Cavet, S.G. Hymowitz, L. Amler, and A. Ashkenazi Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL Nat. Med. 13 2007 1070 1077
113. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C. Schuh, and D.H. Lynch Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med. 5 1999 157 163
114. Y. Wang, K.C. Quon, D.A. Knee, A. Nesterov, and A.S. Kraft RAS, MYC, and sensitivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis Cancer Res. 65 2005 1615 1616
115. N.W. Werneburg, M.E. Guicciardi, S.F. Bronk, S.H. Kaufmann, and G.J. Gores Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins J. Biol. Chem. 282 2007 28960 28970
116. G.S. Wu, T.F. Burns, E.R. McDonald III, W. Jiang, R. Meng, I.D. Krantz, G. Kao, D.D. Gan, J.Y. Zhou, R. Muschel, S.R. Hamilton, N.B. Spinner, S. Markowitz, G. Wu, and W.S. El-Deiry KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene Nat. Genet. 17 1997 141 143
117. Y.H. Wu, C.Y. Yang, W.L. Chien, K.I. Lin, and M.Z. Lai Removal of syndecan-1 promotes TRAIL-induced apoptosis in myeloma cells J. Immunol. 188 2012 2914 2921
118. L. Xu, X. Hu, X. Qu, K. Hou, H. Zheng, and Y. Liu Cetuximab enhances TRAIL-induced gastric cancer cell apoptosis by promoting DISC formation in lipid rafts Biochem. Biophys. Res. Commun. 439 2013 285 290
119. H. Yamaguchi, and H.G. Wang CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells J. Biol. Chem. 279 2004 45495 45502
120. S. Yan, X. Qu, C. Xu, Z. Zhu, L. Zhang, L. Xu, N. Song, Y. Teng, and Y. Liu Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells J. Cancer Res. Clin. Oncol. 138 2012 1279 1289
121. T. Yoshida, A. Maeda, N. Tani, and T. Sakai Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene FEBS Lett. 507 2001 381 385
122. T. Yoshida, T. Shiraishi, M. Horinaka, M. Wakada, and T. Sakai Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin Oncol. Rep. 18 2007 1239 1242
123. T. Yoshida, T. Shiraishi, S. Nakata, M. Horinaka, M. Wakada, Y. Mizutani, T. Miki, and T. Sakai Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein Cancer Res. 65 2005 5662 5667
124. T. Yoshida, Y. Zhang, L.A. Rivera Rosado, and B. Zhang Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells Mol. Cancer Res. 7 2009 1835 1844
125. X.D. Zhang, A.V. Franco, T. Nguyen, C.P. Gray, and P. Hersey Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells J. Immunol. 164 2000 3961 3970
126. Y. Zhang, T. Yoshida, and B. Zhang TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells Cancer Biol. Ther. 8 2009 917 922
127. Y. Zhang, and B. Zhang TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5 Mol. Cancer Res. 6 2008 1861 1871
128. Y. Zhao, S.K. Kalari, P.V. Usatyuk, I. Gorshkova, D. He, T. Watkins, D.N. Brindley, C. Sun, R. Bittman, J.G. Garcia, E.V. Berdyshev, and V. Natarajan Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine kinase 1 J. Biol. Chem. 282 2007 14165 14177
129. B. Zhitomirsky, and Y.G. Assaraf Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance Oncotarget 6 2015 1143 1156
130. W. Zou, X. Liu, P. Yue, Z. Zhou, M.B. Sporn, R. Lotan, F.R. Khuri, and S.Y. Sun c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells Cancer Res. 64 2004 7570 7578